Spago Nanomedical
Spago stays on schedule – green light for phase I/IIa study
Following a positive safety review, Spago Nanomedical's Phase I/IIa study has been granted permission to continue at the highest current dose level. The study is progressing...
News roundup Tuesday, June 3
News roundup Wednesday, May 7
Curasight
News roundup Wednesday April 16
BioArctic
News roundup Wednesday April 9
Takeda
News roundup Thursday, March 20
Alvotech
Spago takes Tumorad-01 study to the next level
Spago Nanomedical has increased the dose of its...
News roundup Tuesday, March 4
Acadia Pharmaceuticals
News roundup Wednesday, January 15
Sanionas
Spago's CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago...
The news sweep Wednesday 6 November
From Seed to Success 2024
The news sweep Wednesday 2 October
BioStock Investing in Life Science
Notes
Senzime's partner receives FDA approval for TetraGraph module
Ellen sells the business for SEK 13,3 million
Oncopeptides increases sales in the second quarter
Alvotech acquires Ivers-Lee Group in Switzerland
OncoZenge enters into convertible loan with Linc
NEWSLETTER
NEWS
AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million
AlzeCure Pharma: “We have good momentum”
Modus Therapeutics CEO comments on latest milestone
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The EU's new life science strategy – a step in the right direction or just fluff?
Early signs of spring in an otherwise frosty biotech landscape
